A retrospective study of feasibility of third-line or higher chemotherapy using pemetrexed in non-squamous, non-small cell lung cancer patients

Fumihiko Hirai, Kaname Nosaki, Taro Ohba, Takuro Kometani, Masafumi Yamaguchi, Motoharu Hamatake, Takashi Seto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticle

Abstract

Objective. We evaluated the feasibility of pemetrexed (PEM) treatment for third-line or higher chemotherapy for non-squamous, non-small cell lung cancer (NSCLC) patients. Methods. We retrospectively analyzed 25 consecutive patients with advanced non-squamous NSCLC who were treated with PEM as third-line or higher chemotherapy between May 2009 and March 2010. Results. Patients composed 15 men and 10 women, with a median age of 67 years (range 51-78 years). The histological subtype was adenocarcinoma in 24 patients and large cell carcinoma in 1 patient. A total of 5 patients had stage IIIB and 20 patients had stage IV disease. The number of prior regimens was 2 in 12 patients, 3 in 4 patients, and 4 or more in 9 patients. The median number of PEM courses was 7. The number of courses was 1 in 3 patients, 24 in 7 patients, 5-9 in 7 patients, and 10 or more in 8 patients. Hematological toxicities of grade 3 or more included leukocytopenia in 3 patients (12.0%), neutrocytopenia in 4 patients (16.0%) and anemia in 1 patient (4.0%). Grade 3 non-hematological toxicity included a rash in 2 patients (8.0%), but no other serious adverse events were observed. A partial response (PR) was observed in 1 patient stable disease (SD) in 18 patients and progressive disease (PD) in 6 patients. The median progression-free survival was 22.0 weeks, and overall survival was 47.8 weeks. Conclusion. PEM treatment might be feasible for third-line or higher chemotherapy for NSCLC patients.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalJapanese Journal of Lung Cancer
Volume51
Issue number4
DOIs
Publication statusPublished - Aug 20 2011

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Retrospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A retrospective study of feasibility of third-line or higher chemotherapy using pemetrexed in non-squamous, non-small cell lung cancer patients. / Hirai, Fumihiko; Nosaki, Kaname; Ohba, Taro; Kometani, Takuro; Yamaguchi, Masafumi; Hamatake, Motoharu; Seto, Takashi; Sugio, Kenji; Ichinose, Yukito.

In: Japanese Journal of Lung Cancer, Vol. 51, No. 4, 20.08.2011, p. 227-232.

Research output: Contribution to journalArticle

Hirai, Fumihiko ; Nosaki, Kaname ; Ohba, Taro ; Kometani, Takuro ; Yamaguchi, Masafumi ; Hamatake, Motoharu ; Seto, Takashi ; Sugio, Kenji ; Ichinose, Yukito. / A retrospective study of feasibility of third-line or higher chemotherapy using pemetrexed in non-squamous, non-small cell lung cancer patients. In: Japanese Journal of Lung Cancer. 2011 ; Vol. 51, No. 4. pp. 227-232.
@article{72e1a2f3dfff4203b6f1656c76a43e2a,
title = "A retrospective study of feasibility of third-line or higher chemotherapy using pemetrexed in non-squamous, non-small cell lung cancer patients",
abstract = "Objective. We evaluated the feasibility of pemetrexed (PEM) treatment for third-line or higher chemotherapy for non-squamous, non-small cell lung cancer (NSCLC) patients. Methods. We retrospectively analyzed 25 consecutive patients with advanced non-squamous NSCLC who were treated with PEM as third-line or higher chemotherapy between May 2009 and March 2010. Results. Patients composed 15 men and 10 women, with a median age of 67 years (range 51-78 years). The histological subtype was adenocarcinoma in 24 patients and large cell carcinoma in 1 patient. A total of 5 patients had stage IIIB and 20 patients had stage IV disease. The number of prior regimens was 2 in 12 patients, 3 in 4 patients, and 4 or more in 9 patients. The median number of PEM courses was 7. The number of courses was 1 in 3 patients, 24 in 7 patients, 5-9 in 7 patients, and 10 or more in 8 patients. Hematological toxicities of grade 3 or more included leukocytopenia in 3 patients (12.0{\%}), neutrocytopenia in 4 patients (16.0{\%}) and anemia in 1 patient (4.0{\%}). Grade 3 non-hematological toxicity included a rash in 2 patients (8.0{\%}), but no other serious adverse events were observed. A partial response (PR) was observed in 1 patient stable disease (SD) in 18 patients and progressive disease (PD) in 6 patients. The median progression-free survival was 22.0 weeks, and overall survival was 47.8 weeks. Conclusion. PEM treatment might be feasible for third-line or higher chemotherapy for NSCLC patients.",
author = "Fumihiko Hirai and Kaname Nosaki and Taro Ohba and Takuro Kometani and Masafumi Yamaguchi and Motoharu Hamatake and Takashi Seto and Kenji Sugio and Yukito Ichinose",
year = "2011",
month = "8",
day = "20",
doi = "10.2482/haigan.51.227",
language = "English",
volume = "51",
pages = "227--232",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "4",

}

TY - JOUR

T1 - A retrospective study of feasibility of third-line or higher chemotherapy using pemetrexed in non-squamous, non-small cell lung cancer patients

AU - Hirai, Fumihiko

AU - Nosaki, Kaname

AU - Ohba, Taro

AU - Kometani, Takuro

AU - Yamaguchi, Masafumi

AU - Hamatake, Motoharu

AU - Seto, Takashi

AU - Sugio, Kenji

AU - Ichinose, Yukito

PY - 2011/8/20

Y1 - 2011/8/20

N2 - Objective. We evaluated the feasibility of pemetrexed (PEM) treatment for third-line or higher chemotherapy for non-squamous, non-small cell lung cancer (NSCLC) patients. Methods. We retrospectively analyzed 25 consecutive patients with advanced non-squamous NSCLC who were treated with PEM as third-line or higher chemotherapy between May 2009 and March 2010. Results. Patients composed 15 men and 10 women, with a median age of 67 years (range 51-78 years). The histological subtype was adenocarcinoma in 24 patients and large cell carcinoma in 1 patient. A total of 5 patients had stage IIIB and 20 patients had stage IV disease. The number of prior regimens was 2 in 12 patients, 3 in 4 patients, and 4 or more in 9 patients. The median number of PEM courses was 7. The number of courses was 1 in 3 patients, 24 in 7 patients, 5-9 in 7 patients, and 10 or more in 8 patients. Hematological toxicities of grade 3 or more included leukocytopenia in 3 patients (12.0%), neutrocytopenia in 4 patients (16.0%) and anemia in 1 patient (4.0%). Grade 3 non-hematological toxicity included a rash in 2 patients (8.0%), but no other serious adverse events were observed. A partial response (PR) was observed in 1 patient stable disease (SD) in 18 patients and progressive disease (PD) in 6 patients. The median progression-free survival was 22.0 weeks, and overall survival was 47.8 weeks. Conclusion. PEM treatment might be feasible for third-line or higher chemotherapy for NSCLC patients.

AB - Objective. We evaluated the feasibility of pemetrexed (PEM) treatment for third-line or higher chemotherapy for non-squamous, non-small cell lung cancer (NSCLC) patients. Methods. We retrospectively analyzed 25 consecutive patients with advanced non-squamous NSCLC who were treated with PEM as third-line or higher chemotherapy between May 2009 and March 2010. Results. Patients composed 15 men and 10 women, with a median age of 67 years (range 51-78 years). The histological subtype was adenocarcinoma in 24 patients and large cell carcinoma in 1 patient. A total of 5 patients had stage IIIB and 20 patients had stage IV disease. The number of prior regimens was 2 in 12 patients, 3 in 4 patients, and 4 or more in 9 patients. The median number of PEM courses was 7. The number of courses was 1 in 3 patients, 24 in 7 patients, 5-9 in 7 patients, and 10 or more in 8 patients. Hematological toxicities of grade 3 or more included leukocytopenia in 3 patients (12.0%), neutrocytopenia in 4 patients (16.0%) and anemia in 1 patient (4.0%). Grade 3 non-hematological toxicity included a rash in 2 patients (8.0%), but no other serious adverse events were observed. A partial response (PR) was observed in 1 patient stable disease (SD) in 18 patients and progressive disease (PD) in 6 patients. The median progression-free survival was 22.0 weeks, and overall survival was 47.8 weeks. Conclusion. PEM treatment might be feasible for third-line or higher chemotherapy for NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=80053550865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053550865&partnerID=8YFLogxK

U2 - 10.2482/haigan.51.227

DO - 10.2482/haigan.51.227

M3 - Article

AN - SCOPUS:80053550865

VL - 51

SP - 227

EP - 232

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 4

ER -